Study of integrative care for large-cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial is looking at an approach to treat large-cell lung cancer. It may help people who have not yet had cancer chemotherapy and who are well enough to do day-to-day activities.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 75 years old or younger
- You have been diagnosed with large-cell lung cancer on pathology (a tissue/bopsy test)
- Your overall health allows normal daily activities (WHO performance status 0 or 1)
- You do not have severe problems with major organs (like heart, liver, or kidneys)
- You have not had any prior cancer chemotherapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is looking at how well a lung cancer treatment improves survival. It enrolls adults with confirmed lung cancer who can safely take the study medicines and have cancer that can be measured on scans.
This trial tests combining chemotherapy, radiation therapy, and two immune-boosting drugs (iparomlimab and tuvonralimab) as a first treatment for locally advanced non-small cell lung cancer that cannot be surgically removed. It aims to see if this combination improves outcomes compared to standard care.
This study will follow people with advanced small cell lung cancer to learn more about how different treatments work in the real world. It may help doctors understand what helps patients live longer and feel better.
This study tests a combination of chemotherapy and immunotherapy in people with advanced non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see how well this treatment works in patients with different levels of daily activity.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
This trial combines surgery to remove the main lung tumor with chemo and an immunotherapy drug called sintilimab. It's for people with advanced non-small cell lung cancer that hasn't been treated before and doesn't have certain gene changes.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.